Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis
IIOS is the largest multi-institutional effort to describe outcomes after IP ICI administration. Clinical outcomes are poor after IP ICI use and IP ICIs should be used with caution.
Authors
- Elizabeth Pršić (ORCID: https://orcid.org/0000-0003-1364-5599)
- Deborah B. Doroshow (ORCID: https://orcid.org/0000-0002-2221-9818)
- Ravi B. Parikh (ORCID: https://orcid.org/0000-0003-2692-6306)
- James Charles Dickerson (ORCID: https://orcid.org/0000-0002-8935-2939)
- Osama Abdelghany
- Joshua E. Reuss (ORCID: https://orcid.org/0000-0002-6401-9080)
- Huili Zhu (ORCID: https://orcid.org/0000-0001-6117-634X)
- Melanie Wain Kier (ORCID: https://orcid.org/0000-0001-8209-0414)
- Hoda E. Sayegh
- John L. Vaughn (ORCID: https://orcid.org/0000-0001-8122-3852)
- Fauzia Riaz (ORCID: https://orcid.org/0000-0002-6267-3839)
- Caleb Hearn (ORCID: https://orcid.org/0000-0001-5843-4926)
- Jacob Peter Zaemes (ORCID: https://orcid.org/0009-0007-4390-5490)
- Samantha Brongiel (ORCID: https://orcid.org/0000-0001-7566-6913)
- Elena Baldwin
- Roger B. Cohen
Institutions
- Baylor College of Medicine (US)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- Yale University (US)
- NYU Langone Health (US)
- Smilow Cancer Hospital (US)
- University of Pennsylvania (US)
- Stanford University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1200/op-24-00788
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27